EU needlestick injuries initiative shelved again:
This article was originally published in Clinica
Executive Summary
For the second time in a fortnight, the European Parliament has had to shelve voting on a demand for EU legislation to reduce the estimated 1 million needlestick injuries reported annually by health professionals (see Clinica No 1209, p 2). Once more, it was bad timing that prevented a vote, since the item was again listed last on the agenda, and MEPs began deserting the chamber for lunch. It was considered unlikely that the necessary "supermajority" of 732 serving members could be reached, so an application has been made for the proposal to be referred back to the Employment and Social Affairs Committee, to wait for a more favourable voting slot.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.